Ocular Therapeutix Stock Forecast, Price & News

-0.31 (-1.91 %)
(As of 04/13/2021 12:00 AM ET)
Today's Range
Now: $15.89
50-Day Range
MA: $18.31
52-Week Range
Now: $15.89
Volume715,106 shs
Average Volume936,332 shs
Market Capitalization$1.21 billion
P/E RatioN/A
Dividend YieldN/A
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
Ocular Therapeutix logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:OCUL
Phone(781) 357-4000
Year FoundedN/A



Sales & Book Value

Annual Sales$4.23 million
Book Value($0.08) per share


Net Income$-86,370,000.00
Net Margins-780.19%
Return on Equity-14,065.71%


Market Cap$1.21 billion
Next Earnings Date5/14/2021 (Estimated)


Ocular Therapeutix (NASDAQ:OCUL) Shares Gap Down to $16.20
April 13, 2021 |
Ocular Therapeutix (NASDAQ:OCUL) Trading Up 7.9%
April 1, 2021 |
Ocular Therapeutix (NASDAQ:OCUL) Stock Price Up 7.9%
April 1, 2021 |
Can Ocular Therapeutix Reach Its Full Potential?
April 1, 2021 |
First Week of OCUL May 21st Options Trading
March 19, 2021 |
Ocular Therapeutix: Q4 Earnings Snapshot
March 11, 2021 |
OCUL December 17th Options Begin Trading
March 10, 2021 |
Preview: Ocular Therapeutix's Earnings
March 10, 2021 |
Ocular Therapeutix Inc hosts conference call for investors
February 28, 2021 |
See More Headlines


Overall MarketRank

1.59 out of 5 stars

Medical Sector

390th out of 2,019 stocks

Pharmaceutical Preparations Industry

181st out of 772 stocks

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
-0.31 (-1.91 %)
(As of 04/13/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OCUL News and Ratings via Email

Sign-up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Ocular Therapeutix (NASDAQ:OCUL) Frequently Asked Questions

Is Ocular Therapeutix a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last twelve months. There are currently 1 hold rating, 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Ocular Therapeutix stock.
View analyst ratings for Ocular Therapeutix
or view top-rated stocks.

What stocks does MarketBeat like better than Ocular Therapeutix?

Wall Street analysts have given Ocular Therapeutix a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Ocular Therapeutix wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Ocular Therapeutix's next earnings date?

Ocular Therapeutix is scheduled to release its next quarterly earnings announcement on Friday, May 14th 2021.
View our earnings forecast for Ocular Therapeutix

How were Ocular Therapeutix's earnings last quarter?

Ocular Therapeutix, Inc. (NASDAQ:OCUL) announced its quarterly earnings data on Thursday, March, 11th. The biopharmaceutical company reported ($1.21) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.18) by $1.03. The biopharmaceutical company earned $7.35 million during the quarter, compared to analyst estimates of $7.73 million. Ocular Therapeutix had a negative net margin of 780.19% and a negative trailing twelve-month return on equity of 14,065.71%.
View Ocular Therapeutix's earnings history

How has Ocular Therapeutix's stock price been impacted by Coronavirus (COVID-19)?

Ocular Therapeutix's stock was trading at $5.35 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, OCUL shares have increased by 197.0% and is now trading at $15.89.
View which stocks have been most impacted by COVID-19

What price target have analysts set for OCUL?

4 analysts have issued 1 year target prices for Ocular Therapeutix's shares. Their forecasts range from $14.00 to $30.00. On average, they anticipate Ocular Therapeutix's share price to reach $24.80 in the next twelve months. This suggests a possible upside of 56.1% from the stock's current price.
View analysts' price targets for Ocular Therapeutix
or view top-rated stocks among Wall Street analysts.

Who are Ocular Therapeutix's key executives?

Ocular Therapeutix's management team includes the following people:
  • Antony Mattessich, President, Chief Executive Officer & Director
  • Patricia Kitchen, Chief Operating Officer
  • Donald Notman, Chief Financial & Accounting Officer
  • Peter Jarrett, Chief Scientific Officer
  • Michael H. Goldstein, Chief Medical Officer & Ophthalmology President

Who are some of Ocular Therapeutix's key competitors?

What other stocks do shareholders of Ocular Therapeutix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ocular Therapeutix investors own include Clearside Biomedical (CLSD), Northwest Biotherapeutics (NWBO), Novavax (NVAX), (CELG), Dynavax Technologies (DVAX), Omeros (OMER), Gilead Sciences (GILD), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO) and SCYNEXIS (SCYX).

What is Ocular Therapeutix's stock symbol?

Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."

How do I buy shares of Ocular Therapeutix?

Shares of OCUL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ocular Therapeutix's stock price today?

One share of OCUL stock can currently be purchased for approximately $15.89.

How much money does Ocular Therapeutix make?

Ocular Therapeutix has a market capitalization of $1.21 billion and generates $4.23 million in revenue each year. The biopharmaceutical company earns $-86,370,000.00 in net income (profit) each year or ($2.01) on an earnings per share basis.

How many employees does Ocular Therapeutix have?

Ocular Therapeutix employs 161 workers across the globe.

What is Ocular Therapeutix's official website?

The official website for Ocular Therapeutix is

Where are Ocular Therapeutix's headquarters?

Ocular Therapeutix is headquartered at 15 CROSBY DRIVE, BEDFORD MA, 01730.

How can I contact Ocular Therapeutix?

Ocular Therapeutix's mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The biopharmaceutical company can be reached via phone at (781) 357-4000 or via email at [email protected]

This page was last updated on 4/14/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.